> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Austedo
- URL: https://www.fdaweb.com/regulatory-review-period-for-austedo/
- Published: 2019-05-13T12:00:00.000Z
- Updated: 2026-09-15T01:26:11.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144092

*Federal Register* notice: FDA has determined that the regulatory review period for Auspex Pharmaceuticals’s Austedo (deutetrabenazine), indicated for treating chorea associated with Huntington’s disease, is 1,736 days, which includes 1,060 days that occurred during the testing phase and 676 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-05-13/pdf/2019-09805.pdf?ref=fdaweb.com).